A226950 Share Price Performance
₩0
-46150.00 (-100.00%)
Price ₩0
Share Pricen/a
OliX Pharmaceuticals, Inc Stock Price
- 0 Narratives written by author
- 0 Comments on narratives written by author
- 0 Fair Values set on narratives written by author
A226950 Community Narratives
There are no narratives available yet.
There are no community narratives available.
Trending Discussion
Recently Updated Narratives
No recently updated narratives available.
Snowflake Analysis
OliX Pharmaceuticals, Inc Key Details
Last Reported Earnings
Dec 31, 2025
Next Reporting Earnings
n/a
- -775.48
- 97.73%
- -107.33%
- 14.7%
About A226950
- Founded
- 2010
- Employees
- 66
- CEO
- WebsiteView website
OliX Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on developing RNA interference (RNAi) therapeutics for dermal, ophthalmic, and pulmonary diseases. The company’s products pipeline includes OLX101A for skin scar; OLX104C for androgenic alopecia; OLX301A for age-related macular degeneration; OLX702A for metabolic dysfunction-associated steatohepatitis; OLX703A for hepatitis; and OLX301D for subretinal fibrosis. The company has a license and collaboration agreement with Hansoh Pharmaceuticals; development collaboration with Korea Institute of Technology; and research collaboration with the University of Virginia. The company was formerly known as Biomolecular Therapeutics Inc. OliX Pharmaceuticals, Inc. was founded in 2010 and is headquartered in Suwon-si, South Korea.